A light-triggerable formulation to control the stability of pro-angiogenic transcription factor hypoxia inducible

Josephine Blersch1, Vitor Francisco, Catarina Rebelo

  • 1Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

Nanoscale
|May 1, 2020
PubMed

Insights

Researchers developed novel light-triggerable nanoparticles for targeted gene silencing of hypoxia-inducible factor 1-alpha (HIF-1α). This new delivery system enhances endothelial cell targeting and improves small interfering RNA (siRNA) delivery efficiency for treating related diseases.

Area of Science:

  • Biomedical Engineering
  • Molecular Biology
  • Nanotechnology

Background:

  • Hypoxia-inducible factor 1-alpha (HIF-1α) is crucial for vascular remodeling in diseases like cancer and ischemic heart disease.
  • Small interfering RNA (siRNA) gene silencing is a therapeutic strategy for HIF-1α, but current delivery systems lack endothelial targeting and efficiency.

Purpose of the Study:

  • To develop a light-triggerable polymeric nanoparticle (NP) library for efficient and targeted siRNA delivery to regulate HIF-1α.
  • To identify NP formulations with enhanced endothelial cell targeting and superior gene knockdown efficacy compared to commercial agents.

Main Methods:

  • Synthesized a library of 110 light-triggerable polymeric nanoparticles with varying properties.
  • Screened NP formulations for siRNA delivery efficiency and gene knockdown of HIF-1α.
  • Evaluated the targeting specificity of the most efficient NPs towards endothelial cells using a two-step methodology.

Main Results:

  • Over 35% of the NP formulations outperformed commercial transfection agents in gene knockdown.
  • Identified a specific NP formulation demonstrating exquisite targeting to endothelial cells.
  • The selected NP formulation achieved more efficient siRNA delivery for modulating HIF-1α than commercial agents.

Conclusions:

  • The developed light-triggerable NPs offer a promising strategy for targeted gene silencing of HIF-1α.
  • This approach significantly enhances intracellular siRNA delivery efficiency and tissue-specific regulation.
  • The findings pave the way for improved therapeutic interventions in HIF-1α-related diseases.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.3K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.5K
Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.0K